Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Cancer-associated fibroblast heterogeneity, activation and function: implications for prostate cancer

Owen, Jasmine S., Clayton, Aled ORCID: and Pearson, Helen B. ORCID: 2022. Cancer-associated fibroblast heterogeneity, activation and function: implications for prostate cancer. Biomolecules 13 (1) , 67. 10.3390/biom13010067

[thumbnail of biomolecules-13-00067-v3.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (2MB)


The continuous remodeling of the tumor microenvironment (TME) during prostate tumorigenesis is emerging as a critical event that facilitates cancer growth, progression and drug-resistance. Recent advances have identified extensive communication networks that enable tumor–stroma cross-talk, and emphasized the functional importance of diverse, heterogeneous stromal fibroblast populations during malignant growth. Cancer-associated fibroblasts (CAFs) are a vital component of the TME, which mediate key oncogenic events including angiogenesis, immunosuppression, metastatic progression and therapeutic resistance, thus presenting an attractive therapeutic target. Nevertheless, how fibroblast heterogeneity, recruitment, cell-of-origin and differential functions contribute to prostate cancer remains to be fully delineated. Developing our molecular understanding of these processes is fundamental to developing new therapies and biomarkers that can ultimately improve clinical outcomes. In this review, we explore the current challenges surrounding fibroblast identification, discuss new mechanistic insights into fibroblast functions during normal prostate tissue homeostasis and tumorigenesis, and illustrate the diverse nature of fibroblast recruitment and CAF generation. We also highlight the promise of CAF-targeted therapies for the treatment of prostate cancer.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
European Cancer Stem Cell Research Institute (ECSCRI)
Publisher: MDPI
ISSN: 2218-273X
Date of First Compliant Deposit: 9 January 2023
Date of Acceptance: 27 December 2022
Last Modified: 05 May 2023 15:15

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics